CEDRA Corporation is First North American Clinical Research Organization to Offer Gyrolab Instrumentation

AUSTIN, Texas--(BUSINESS WIRE)--CEDRA Corporation, a division of Worldwide Clinical Trials, announced today that it has purchased the Gyrolab™ xP workstation for use in its bioanalytical research, specifically for ligand binding analysis. CEDRA is employing the new Gyrolab in its Ligand Binding Assay (LBA) laboratory in Austin, Texas, and is the only CRO in North America to offer this technology to the pharmaceutical industry.

“We believe the addition of the Gyrolab to our LBA laboratories is significant and represents our dedication to enhancing the capabilities offered to the biopharmaceutical research industry”

The Gyrolab represents significant innovation in the automation and advancement of bioanalytical research. The patented technology transforms the numerous steps involved in conventional LBA applications and streamlines them into single, nanoliter-scale procedures. Efficiency and productivity are significantly boosted with the Gyrolab’s ability to miniaturize and integrate assay steps for protein quantification immunoassays.

“We believe the addition of the Gyrolab to our LBA laboratories is significant and represents our dedication to enhancing the capabilities offered to the biopharmaceutical research industry,” said William Nowatzke, Ph.D., Director, Ligand Binding Assay Group, CEDRA Corporation. “A key driver to our business is the dedication to staying on the forefront of technology. The addition of the Gyrolab complements our other four LBA platforms, permitting CEDRA to transfer or develop practically any LBA method. One of the key strengths of the Gyrolab is its miniaturized assay format requiring extremely small sample volumes—nanoliters—ultimately minimizing the consumption of precious sample volume,” continued Dr. Nowatzke. “It eliminates cumbersome multiplexing practices.”

About CEDRA

CEDRA Corporation, a division of Worldwide Clinical Trials, offers a full range of Phase I-IIb clinical research and bioanalytical services, as well as specialized studies to the pharmaceutical/biotech and medical device industries. CEDRA’s combination of a state-of-the-art bioanalytical laboratory with clinical research sites allows them to play an important role in drug development programs. To learn more about CEDRA, visit www.cedracorp.com.

About Gyros

The Gyrolab is developed and manufactured by Gyros, globally headquartered in Uppsala, Sweden. Gyrolab systems are used throughout all phases of clinical research to accelerate the development of therapeutic proteins from early drug screening through late-phase clinical trials. To learn more about Gyros, visit www.gyros.com